{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "527208", "DateCompleted": {"Year": "1980", "Month": "04", "Day": "25"}, "DateRevised": {"Year": "2019", "Month": "08", "Day": "27"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0344-5704", "JournalIssue": {"Volume": "3", "Issue": "3", "PubDate": {"Year": "1979"}}, "Title": "Cancer chemotherapy and pharmacology", "ISOAbbreviation": "Cancer Chemother Pharmacol"}, "ArticleTitle": "Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.", "Pagination": {"StartPage": "181", "EndPage": "188", "MedlinePgn": "181-8"}, "Abstract": {"AbstractText": ["Crystalline 4-(SR)-sulfidocyclophosphamides, sulfido derivatives of activated cyclophosphamide (4-hydroxycyclophosphamide), were synthesized by ozonation of cyclophosphamide and reaction of the intermediate 4-hydroxycyclophosphamide with various thiols (HSR). The products were characterized by elemental analysis, 1H NMR and IR spectroscopy, and mass spectrometry. 1H NMR and polarimetric analysis demonstrated that they consist of racemic cis-isomers that are stable in the crystalline state at room temperature. In aqueous solution these derivatives are hydrolyzed to 4-hydroxycyclophosphamide and the corresponding thiol, with half-lives ranging between 4 and 17 min at 37 degrees C and pH 7. The cytotoxicity of 4-(S-ethyl)- and 4-(S-ethanol)-sulfidocyclophosphamide against Yoshida sarcoma ascites cells and the toxicity in rats were found to be practically identical with those of activated cyclophosphamide. A preliminary evaluation of the curative effect after a single IV injection of 4-(S-ethane)- and 4-(S-ethanol)-sulfidocyclophosphamide in rats bearing Yoshida ascites sarcoma or of 4-(S-ethanol)-sulfidocyclophosphamide in nu/nu mice bearing human breast carcinoma xenografts suggested that these sulfido derivatives possess the same oncostatic efficacy as activated cyclophosphamide itself."]}, "AuthorList": [{"AffiliationInfo": [], "Identifier": [], "LastName": "Peter", "ForeName": "G", "Initials": "G"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hohorst", "ForeName": "H J", "Initials": "HJ"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Cancer Chemother Pharmacol", "NlmUniqueID": "7806519", "ISSNLinking": "0344-5704"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "8N3DW7272P", "NameOfSubstance": "Cyclophosphamide"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Chemical Phenomena"}, {"QualifierName": [], "DescriptorName": "Chemistry"}, {"QualifierName": ["analogs & derivatives", "chemical synthesis", "pharmacology"], "DescriptorName": "Cyclophosphamide"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Hydrolysis"}, {"QualifierName": [], "DescriptorName": "Lethal Dose 50"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Rats"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Cancer Treat Rep. 1976 Apr;60(4):355-9", "ArticleIdList": ["1277211"]}, {"Citation": "Cancer Treat Rep. 1976 Apr;60(4):509-16", "ArticleIdList": ["1277228"]}, {"Citation": "Chem Pharm Bull (Tokyo). 1977 Aug;25(8):1877-91", "ArticleIdList": ["562722"]}, {"Citation": "Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 May 31;91(2):127-42", "ArticleIdList": ["27021"]}, {"Citation": "Cancer Treat Rep. 1976 Apr;60(4):369-72", "ArticleIdList": ["945125"]}, {"Citation": "Biomed Mass Spectrom. 1977 Aug;4(4):209-15", "ArticleIdList": ["912018"]}, {"Citation": "Cancer Treat Rep. 1976 Apr;60(4):429-35", "ArticleIdList": ["1277218"]}, {"Citation": "Cancer Treat Rep. 1976 Apr;60(4):309-15", "ArticleIdList": ["1277206"]}, {"Citation": "J Cancer Res Clin Oncol. 1979 Apr 12;93(3):233-40", "ArticleIdList": ["468886"]}, {"Citation": "Cancer Treat Rep. 1976 Apr;60(4):301-8", "ArticleIdList": ["1277205"]}, {"Citation": "J Biol Chem. 1948 Aug;175(1):67-71", "ArticleIdList": ["18873279"]}, {"Citation": "J Med Chem. 1974 Nov;17(11):1237-9", "ArticleIdList": ["4416021"]}, {"Citation": "Cancer Res. 1976 Jul;36(7 PT 1):2278-81", "ArticleIdList": ["945124"]}, {"Citation": "Arzneimittelforschung. 1974 Aug;24(8):1172-6", "ArticleIdList": ["4479392"]}, {"Citation": "Biochem Pharmacol. 1974 Jan 1;23(1):115-29", "ArticleIdList": ["4811053"]}, {"Citation": "Arzneimittelforschung. 1963 Dec;13:1021-31", "ArticleIdList": ["14208670"]}]}], "History": [{"Year": "1979", "Month": "1", "Day": "1"}, {"Year": "1979", "Month": "1", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1979", "Month": "1", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["527208", "10.1007/BF00262420"]}}], "PubmedBookArticle": []}